TIBER CREEK GROUP for PHRMA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues related to the United States-Mexico-Canada-Agreement (USMCA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
Copyright/Patent/Trademark CPT
Issues related to pharmaceutical patents
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER OLSON | — |
Health Issues HCR
Issues related to pharmaceutical drug pricing and transparency. Issues related to the illegal importation of prescription drugs. Issues related to capping out of pocket costs. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Issues related to pharmaceutical copayments within the CMS Proposed Notice of Benefit and Payment Parameters Rule for 2021
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
Medicare/Medicaid MMM
Issues related to Medicare Part B pricing reform. Issues related to Medicare Part D pricing reform. Proposal to eliminate Medicaid inflationary cap. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. Issues related to pharmaceutical copayments within the CMS Proposed Notice of Benefit and Payment Parameters Rule for 2021
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| MATTHEW LEFFINGWELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.